DK0736004T3 - (2,4-disulfophenyl)-N-t-butylnitron, salte heraf og deres anvendelse som indfangningsmidler til farmaceutiske radikaler - Google Patents

(2,4-disulfophenyl)-N-t-butylnitron, salte heraf og deres anvendelse som indfangningsmidler til farmaceutiske radikaler

Info

Publication number
DK0736004T3
DK0736004T3 DK95907224T DK95907224T DK0736004T3 DK 0736004 T3 DK0736004 T3 DK 0736004T3 DK 95907224 T DK95907224 T DK 95907224T DK 95907224 T DK95907224 T DK 95907224T DK 0736004 T3 DK0736004 T3 DK 0736004T3
Authority
DK
Denmark
Prior art keywords
nervous system
central nervous
pharmaceutical
salts
butylnitron
Prior art date
Application number
DK95907224T
Other languages
Danish (da)
English (en)
Inventor
John M Carney
Original Assignee
Oklahoma Med Res Found
Univ Kentucky Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Med Res Found, Univ Kentucky Res Found filed Critical Oklahoma Med Res Found
Application granted granted Critical
Publication of DK0736004T3 publication Critical patent/DK0736004T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/45—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/46—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton having the sulfo groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK95907224T 1993-12-23 1994-12-22 (2,4-disulfophenyl)-N-t-butylnitron, salte heraf og deres anvendelse som indfangningsmidler til farmaceutiske radikaler DK0736004T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/173,579 US5488145A (en) 1993-12-23 1993-12-23 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
PCT/US1994/014545 WO1995017876A2 (fr) 1993-12-23 1994-12-22 2,4-disulfophenyl butylnitrone, ses sels et leur utilisation comme pieges de spin pharmaceutiques

Publications (1)

Publication Number Publication Date
DK0736004T3 true DK0736004T3 (da) 2000-10-09

Family

ID=22632663

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95907224T DK0736004T3 (da) 1993-12-23 1994-12-22 (2,4-disulfophenyl)-N-t-butylnitron, salte heraf og deres anvendelse som indfangningsmidler til farmaceutiske radikaler

Country Status (28)

Country Link
US (4) US5488145A (fr)
EP (1) EP0736004B1 (fr)
JP (3) JP3412821B2 (fr)
KR (1) KR100370522B1 (fr)
CN (1) CN1070176C (fr)
AT (1) ATE192736T1 (fr)
AU (1) AU679835B2 (fr)
BR (2) BR9408378A (fr)
CA (1) CA2179521C (fr)
CZ (1) CZ289629B6 (fr)
DE (1) DE69424441T2 (fr)
DK (1) DK0736004T3 (fr)
ES (1) ES2145264T3 (fr)
FI (1) FI111718B (fr)
GR (1) GR3034134T3 (fr)
HR (1) HRP950358B1 (fr)
HU (1) HU221167B1 (fr)
MY (1) MY114178A (fr)
NO (1) NO306457B1 (fr)
NZ (1) NZ279025A (fr)
PL (1) PL185189B1 (fr)
PT (1) PT736004E (fr)
RU (1) RU2159231C2 (fr)
SG (1) SG64903A1 (fr)
SK (1) SK282403B6 (fr)
TW (1) TW299315B (fr)
UA (1) UA45964C2 (fr)
WO (1) WO1995017876A2 (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723502A (en) * 1985-07-18 1998-03-03 Proctor; Peter H. Topical spin trap composition and method
US5622994A (en) * 1989-10-17 1997-04-22 Oklahoma Medical Research Foundation Spin trapping pharmaceutical compositions and methods for use thereof
EP0496796B1 (fr) * 1989-10-17 1994-08-31 Oklahoma Medical Research Foundation Procede et compositions inhibant les troubles associes aux lesions oxydatives des tissus
US6002001A (en) * 1991-06-18 1999-12-14 Oklahoma Medical Research Foundation Spin trapping pharmaceutical compositions and methods for use thereof
US20050107366A1 (en) * 1991-06-18 2005-05-19 Carney John M. Spin trapping pharmaceutical compositions and methods for use thereof
US20040208875A1 (en) * 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
DE69634647T2 (de) * 1995-09-11 2006-03-02 Aventis Pharmaceuticals Inc. Cyclische Nitrone und pharmazeutische Mittel die sie enthalten
WO1997019054A1 (fr) 1995-11-17 1997-05-29 Florida International University Agents de piegeage de spin a base d'azulenyl-nitrones, et leurs procedes de fabrication et d'utilisation
EP0949915A4 (fr) * 1996-04-17 2001-07-04 Oklahoma Med Res Found Traitement de la demence associee a l'infection par le virus du sida (vih-1) au moyen de pieges a radicaux libres a base de nitrone
EP1021430A1 (fr) * 1996-07-19 2000-07-26 Centaur Pharmaceuticals, Inc. Composes de nitrone furannique
TW429241B (en) * 1996-09-26 2001-04-11 Sumitomo Pharma Nitrone derivatives
MA26553A1 (fr) * 1997-10-17 2004-12-20 Centaur Pharmaceuticals Inc Alpha-aryl-n-alkylnitrones et compositions pharmaceutiques contenant ceux-la
NZ505757A (en) * 1998-01-16 2002-09-27 Centaur Pharmaceuticals Inc Thioether furan nitrone compounds and pharmaceuticals thereof; useful for the treatment or prophylaxis of neurodegenerative, autoimmune and inflammatory conditions
JP2002509147A (ja) * 1998-01-16 2002-03-26 センター ファーマシューティカルズ， インコーポレイテッド チオフェンニトロン化合物
US6255353B1 (en) * 1998-03-13 2001-07-03 Centaur Pharmaceuticals, Inc. Inhibition of angiogenesis
US6083989A (en) * 1999-05-18 2000-07-04 Centaur Pharmaceuticals, Inc. Aryl nitrone therapeutics for the treatment of inflammatory bowel disease
CA2333190A1 (fr) * 1998-05-19 1999-11-25 Beverly Greenwood-Van Meerveld Medicament a base de nitrone furanique, destine au traitement des affections inflammatoires de l'intestin
US6730700B2 (en) * 1998-12-02 2004-05-04 Renovis, Inc. 3,4,5,-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same
UA66401C2 (en) 1998-12-02 2004-05-17 Sentor Pharmaceuticals Inc 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical composition containing the same
EP1155019B1 (fr) 1999-01-25 2005-12-07 National Jewish Medical and Research Center Porphyrines substituees et leur utilisation therapeutique
NZ543319A (en) * 1999-04-28 2007-06-29 Neurochem Int Ltd Compositions and methods for treating amyloidosis using sulphonate derivatives
BR9904931A (pt) * 1999-10-18 2001-06-12 Sergio Teixeira Ferreira Inibição de amiloidoses
US6815425B1 (en) 1999-10-22 2004-11-09 The United States Of America As Represented By The Secretary Of The Army Pharmaceutical composition containing pGLU-GLU-PRO-NH2 and method for treating diseases and injuries to the brain, spinal cord and retina using same
AU1574701A (en) * 1999-10-22 2001-04-30 Wrair Walter Reed Army Institute Of Research A pharmaceutical composition containing pglu-glu-pro-nh2 and method for treating diseases and injuries to the brain, spinal cord and retina using same
WO2001051459A1 (fr) * 2000-01-10 2001-07-19 Centaur Phamaceuticals, Inc. Methode de purification des acides et des sels sulfoniques aryles
SE0000056D0 (sv) 2000-01-10 2000-01-10 Astrazeneca Ab Novel process
SE0000055D0 (sv) 2000-01-10 2000-01-10 Centaur Pharmaceuticals Inc Novel process
SE0001916D0 (sv) * 2000-05-23 2000-05-23 Astrazeneca Ab Novel formulation
US6664297B1 (en) 2000-10-18 2003-12-16 Universidade Federal Do Rio De Janeiro Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol
WO2002065993A2 (fr) 2001-01-08 2002-08-29 Centaur Pharmaceuticals, Inc. Utilisation de composes d'arylnitrone dans des methodes de traitement des douleurs neuropathiques
WO2003010154A1 (fr) * 2001-07-26 2003-02-06 Samsung Electronics Co. Ltd. Composes seleno contenant un groupe fonctionnel nitron, leur preparation et leurs applications therapeutiques
US20030045461A1 (en) * 2001-09-06 2003-03-06 Jen-Chang Hsia Composition and methods of esterified nitroxides gated with carboxylic acids
FR2846968B1 (fr) * 2002-11-08 2005-02-04 Salles Jean Pierre Nouveaux derives amphiphiles de l'alpha-c-phenyl-n-tert- butyl nitrone
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US20050059638A1 (en) * 2003-08-04 2005-03-17 Kelly Michael G. Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders
US20050182060A1 (en) * 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds
BRPI0517790A (pt) * 2004-11-12 2008-10-21 Neurochem Int Ltd métodos e composições fluoradas para tratar doenças relacionadas à amilóide
CA2586334A1 (fr) * 2004-11-16 2006-06-08 Neurochem (International) Limited Composes pour le traitement de maladies associees au snc et a la proteine amyloide
WO2006085149A2 (fr) 2004-12-22 2006-08-17 Neurochem (International) Limited Methodes et compositions de traitement de maladies liees a l'amyloide
US20060235370A1 (en) * 2005-04-04 2006-10-19 Oblong John E Method of regulating mammalian keratinous tissue
TW200716088A (en) * 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
WO2007013843A1 (fr) * 2005-07-26 2007-02-01 Astrazeneca Ab Utilisation de 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate n-oxyde) contre l'ischemie myocardique
WO2007013844A1 (fr) * 2005-07-26 2007-02-01 Astrazeneca Ab Utilisation de 4-[(tert-butylimino)benzene-1,3-disulfonate n-oxyde contre les nausees
WO2007013841A1 (fr) * 2005-07-26 2007-02-01 Astrazeneca Ab Utilisation de 4-((tert-butylimine)methyl) benzene-1,3-disulfonate n-oxide pour lutter contre un oedeme cerebral
WO2007013842A1 (fr) * 2005-07-26 2007-02-01 Astrazeneca Ab Utilisation de 4-((tert-butylimino)methyl) benzene-1,3-disulfonate n-oxyde contre les transformations hemorragiques du cerveau
MX2008008213A (es) * 2005-12-22 2008-09-03 Neurochem Int Ltd Tratamiento de trastornos renales, nefropatia diabetica y dislipidemias.
WO2008013866A2 (fr) * 2006-07-25 2008-01-31 Hough Ear Institute Procédé de traitement de traumatisme acoustique aigu
KR101608445B1 (ko) 2006-10-12 2016-04-01 비에이치아이 리미티드 파트너쉽 3-아미노-1-프로판설폰산을 전달하기 위한 방법, 화합물, 조성물 및 비히클
EP2120905A1 (fr) * 2006-12-22 2009-11-25 BELLUS Health (International) Limited Procédés, composés et compositions permettant de traiter des troubles métaboliques et le diabète
US20090082454A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched disufenton
US8425593B2 (en) 2007-09-26 2013-04-23 St. Jude Medical, Inc. Collapsible prosthetic heart valves
EP2242360B1 (fr) * 2008-02-12 2015-04-08 Tosk, Inc. Adjuvants a la doxorubicine pour reduire la toxicite et leurs procedes d'utilisation
US11382895B2 (en) * 2008-05-23 2022-07-12 National Jewish Health Methods for treating injury associated with exposure to an alkylating species
ES2398339T3 (es) * 2008-09-02 2013-03-15 Oklahoma Medical Research Foundation 2,4-disulfonil fenil terc-butil nitrona para el tratamiento de gliomas
AU2010289838C1 (en) * 2009-08-24 2014-03-06 Hough Ear Institute Methods for treating acute acoustic trauma
ES2893825T3 (es) 2011-02-04 2022-02-10 Hough Ear Inst Métodos de tratamiento de lesiones cerebrales
JP2019537582A (ja) 2016-10-31 2019-12-26 ハフ イアー インスティテュート シナプス形成および神経突起形成を増強するための方法
EP3570826A4 (fr) 2017-01-19 2020-09-23 Otologic Pharmaceutics, Inc. Formulations de n-acétylcystéine et leurs utilisations
US11660280B2 (en) 2017-09-20 2023-05-30 Oklahoma Medical Research Foundation Treatment of drug resistant gliomas
US10829441B2 (en) 2017-11-14 2020-11-10 The University Of Toledo Reactive oxygen species-sensitive nitric oxide synthase inhibitors for the treatment of ischemic stroke
WO2019213245A1 (fr) 2018-05-03 2019-11-07 Hough Ear Institute Procédés de réduction de la protéine tau pathologique accumulée
KR102899320B1 (ko) 2018-09-12 2025-12-12 호 이어 인스티튜트 인공 와우 수술에 따른 난청의 치료 방법
WO2021173702A1 (fr) * 2020-02-24 2021-09-02 Oblato, Inc. Compositions et méthodes de traitement de cancers et de tumeurs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3914650A1 (de) * 1989-05-03 1990-11-08 Basf Ag Neue phenylendiamine sowie ein verfahren zur herstellung von phenylendiaminen
EP0496796B1 (fr) * 1989-10-17 1994-08-31 Oklahoma Medical Research Foundation Procede et compositions inhibant les troubles associes aux lesions oxydatives des tissus
US5036097A (en) * 1989-10-17 1991-07-30 Oklahoma Medical Research Foundation Phenylbutyl nitrone compositions and methods for prevention of gastric ulceration
US5025032A (en) * 1989-10-17 1991-06-18 Oklahoma Medical Research Foundation Phenyl butyl nitrone compositions and methods for treatment of oxidative tissue damage
DE3937342A1 (de) * 1989-11-09 1991-05-16 Bayer Ag Verfahren zur herstellung von 2-aminobenzol-disulfonsaeuren-(1,4) und die neue verbindung 6-chlor-2-aminobenzol-disulfonsaeure-(1,4)
EP0590072B1 (fr) * 1991-06-18 2001-12-05 Oklahoma Medical Research Foundation Emploi du blocage par spin pour le traitement de maladies associees a l'oxydation des lipides et des proteines
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps

Also Published As

Publication number Publication date
US5780510A (en) 1998-07-14
BR1100626A (pt) 1999-11-23
FI111718B (fi) 2003-09-15
WO1995017876A3 (fr) 1995-08-10
RU2159231C2 (ru) 2000-11-20
KR100370522B1 (ko) 2003-05-16
CN1070176C (zh) 2001-08-29
JPH09507232A (ja) 1997-07-22
HUT76788A (en) 1997-11-28
WO1995017876A2 (fr) 1995-07-06
NO306457B1 (no) 1999-11-08
GR3034134T3 (en) 2000-11-30
CA2179521C (fr) 2002-03-19
ES2145264T3 (es) 2000-07-01
JP2004075696A (ja) 2004-03-11
NO962637L (no) 1996-08-13
HRP950358B1 (en) 2001-04-30
NZ279025A (en) 1998-02-26
US5488145A (en) 1996-01-30
HRP950358A2 (en) 1997-08-31
JP3412821B2 (ja) 2003-06-03
CZ177596A3 (en) 1996-12-11
HU9601739D0 (en) 1996-08-28
PL315154A1 (en) 1996-10-14
SK78896A3 (en) 1997-09-10
ATE192736T1 (de) 2000-05-15
SK282403B6 (sk) 2002-01-07
UA45964C2 (uk) 2002-05-15
JP2001010953A (ja) 2001-01-16
PL185189B1 (pl) 2003-03-31
US5475032A (en) 1995-12-12
AU679835B2 (en) 1997-07-10
CZ289629B6 (cs) 2002-03-13
DE69424441T2 (de) 2000-10-12
BR9408378A (pt) 1997-08-19
FI962589L (fi) 1996-08-20
SG64903A1 (en) 1999-05-25
TW299315B (fr) 1997-03-01
HK1008294A1 (en) 1999-05-07
AU1552795A (en) 1995-07-17
FI962589A0 (fi) 1996-06-20
NO962637D0 (no) 1996-06-20
DE69424441D1 (de) 2000-06-15
HK1001768A1 (en) 1998-07-10
EP0736004A1 (fr) 1996-10-09
EP0736004B1 (fr) 2000-05-10
CN1156447A (zh) 1997-08-06
PT736004E (pt) 2000-09-29
CA2179521A1 (fr) 1995-07-06
MY114178A (en) 2002-08-30
US5508305A (en) 1996-04-16
HU221167B1 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
NO962637L (no) 2,4-disulfonylfenylbutylnitron, salter derav og anveldelse som farmasöytiske midler
NZ512883A (en) 2-oxoquinoline compounds and medicinal uses thereof
NO981944D0 (no) Lipopolyaminer som transfeksjonsmidler samt farmas÷ytisk anvendelse derav
NO20053104D0 (no) Oral, analgesisk doseringsform med forlenget frigivelse for administrering ±n gang pr. dag.
DE69808130D1 (de) Adamantan-derivate
ES2159591T3 (es) Composicion de liberacion controlada.
SE9704545D0 (sv) Novel compounds
DK0733046T3 (da) Benzoylguanidiner, deres fremstilling og anvendelse i medikamenter
EE04606B1 (et) H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks
DE68909412D1 (de) Salze von glykosaminoglykanen, verfahren zu ihrer herstellung und diese salze enthaltende pharmazeutische zusammensetzungen.
BG108452A (en) Tablet comprising cetirizine and pseudoephedrine
NO955313D0 (no) Anvendelse av ropivacain i fremstillingen av et farmasöytikum med analgetisk effekt som har minimal motorisk blokkering
MY128529A (en) Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
DK0742716T3 (da) Farmaceutisk sammensætning til systemisk transdermal indgivelse med det aktive middel morphin-6-glucuronid
ES2065855B1 (es) Procedimiento para la preparacion de nuevos derivados desoxiazafosfolipidicos con accion inhibidora de la fosfolipasa a2, nuevos derivados desoxiazafosfolipidicos obtenidos y utilizacion de los mismos.
AR035986A1 (es) Uso de derivados anti-convulsivos para la manufactura de un medicamento util para el tratamiento del temblor esencial
ATE227984T1 (de) Mittel gegen malaria und babesia und diese enthaltende pfarmazeutische zubereitungen
YU49496B (sh) 2,4-disulfofenil butil nitron, njegove soli, i njihova primena kao farmaceutskih kompozicija
CO4180553A1 (es) Composiciones para el tratamiento de la peridontitis adulta